Immune Regulation News Volume 11.28 | Aug 2 2019

TOP STORY

CD24 Signaling through Macrophage Siglec-10 Is a Target for Cancer Immunotherapy

Researchers demonstrated a role for tumor-expressed CD24 in promoting immune evasion through its interaction with the inhibitory receptor sialic-acid-binding Ig-like lectin 10 (Siglec-10), which was expressed by tumor-associated macrophages. [Nature] Abstract | Press Release

(Ranked by impact factor of the journal)

Laboratory Mice Born to Wild Mice Have Natural Microbiota and Model Human Immune Responses

Scientists transferred C57BL/6 embryos into wild mice, creating “wildlings.” These mice had a natural microbiota and pathogens at all body sites and the tractable genetics of C57BL/6 mice. The bacterial microbiome, mycobiome, and virome of wildlings affected the immune landscape of multiple organs. [Science] Abstract | Press Release | Graphical Abstract

Identification of a T Follicular Helper Cell Subset that Drives Anaphylactic IgE

Investigators report a rare population of IL-13-producing T follicular helper cells present in mice and humans with IgE to allergens, but not when allergen-specific IgE was absent or only low-affinity. [Science] Abstract | Press Release

The Transcription Factor TCF-1 Enforces Commitment to the Innate Lymphoid Cell Lineage

Through the use of single-cell approaches, the authors examined the transcriptional and functional heterogeneity of innate lymphoid cell progenitors, and studied the precursor-product relationships that link the subsets identified. [Nat Immunol] Abstract

IFN-β Is a Macrophage-Derived Effector Cytokine Facilitating the Resolution of Bacterial Inflammation

Using a transcriptomic analysis of macrophage subsets, researchers showed that non-phagocytic resolution phase macrophages expressed a distinct IFN-β-related gene signature in mice. [Nat Commun] Full Article

Activation of DR3 Signaling Causes Loss of ILC3s and Exacerbates Intestinal Inflammation

Scientists report that activation of death receptor 3 (DR3) signaling by an agonistic anti-DR3 antibody increased GM-CSF production from group 3 innate lymphoid cells (ILC3s) through the p38 MAPK pathway. GM-CSF caused accumulation of eosinophils, neutrophils and CD11b⁺CD11c⁺ myeloid cells, resulting in loss of ILC3s from the intestine in an IL-23-dependent manner and exacerbating colitis. [Nat Commun] Full Article

Treating Ischemia via Recruitment of Antigen-Specific T Cells

Investigators explored the hypothesis that implantation of an antigen-releasing scaffold, in animals previously vaccinated with the same antigen, could concentrate T_H2 T cells and enhance vascularization of ischemic tissue. [Sci Adv] Full Article | Press Release

STAT6 Induces Expression of Gas6 in Macrophages to Clear Apoptotic Neutrophils and Resolve Inflammation

The authors investigated the role of alveolar macrophage polarization and expression of the efferocytic ligand Gas6 in restoring homeostasis. In the murine model of lipopolysaccharide-induced acute lung injury, they observed augmented temporal generation of cytokines IL-4 and TSG6 in bronchoalveolar fluid. [Proc Natl Acad Sci USA] Full Article | Press Release

Monocytes Acquire the Ability to Prime Tissue-Resident T Cells via IL-10-Mediated TGF-β Release

Blocking IL-10 reduced CD103 expression on human T cells stimulated in vitro with the adjuvant combination as well as diminished CD103 on lung-resident T cells in vivo in mice. [Cell Rep] Full Article | Graphical Abstract

IL-29 Promoted Obesity-Induced Inflammation and Insulin Resistance

Researchers explored the function of interleukin-29 (IL-29) in the pathogenesis of obesity-induced inflammation and insulin resistance. They found that serum IL-29 level was significantly higher in obese patients. [Cell Mol Immunol] Abstract

Neutrophil Recruitment and Activation Are Differentially Dependent on MyD88/TRIF and MAVS Signaling during RSV Infection

Scientists showed that MyD88/TRIF signaling was essential for lung neutrophil recruitment while MAVS signaling, leading to type I IFN production, was necessary for neutrophil activation. [Mucosal Immunol] Full Article

Subscribe to our sister publications: Human Immunology News & Immunology of Infectious Disease News.

Targeting Metabolism to Regulate Immune Responses in Autoimmunity and Cancer

Metabolic programming is emerging as a critical mechanism to alter immune cell activation, differentiation and function. Targeting metabolism does not completely suppress or activate the immune system but selectively regulates immune responses. [Nat Rev Drug Discov] Abstract

Macrophages at CNS Interfaces: Ontogeny and Function in Health and Disease

The segregation and limited regenerative capacity of the CNS necessitate a specialized and tightly regulated resident immune system that continuously guards the CNS against invading pathogens and injury. [Nat Rev Neurosci] Abstract

Visit our reviews page to see a complete list of reviews in the immune regulation research field.

Momenta Pharmaceuticals Launches Phase II/III Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and Is Granted FDA Fast Track Designation

Momenta Pharmaceuticals, Inc. announced the launch of an adaptive Phase II/III clinical study for its FcRn inhibitor nipocalimab (M281) in warm Autoimmune Hemolytic Anemia. [Momenta Pharmaceuticals, Inc.] Press Release

Abivax Treats First Patient in Phase IIa Rheumatoid Arthritis Clinical Trial of ABX464

Abivax announced that the first patient was dosed in study ABX464-301, a Phase IIa clinical trial of ABX464 to treat patients with moderate to severe active rheumatoid arthritis. [Abivax] Press Release

Spring Bank Announces FDA Acceptance of IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors

Spring Bank Pharmaceuticals, Inc. announced that its Investigational New Drug (IND) application for a Phase I trial of SB 11285, the company’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist development candidate, is now effective following clearance by the FDA. [Spring Bank Pharmaceuticals, Inc.] Press Release

I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase I Trial of the CD73 Antibody TJD5 in the US in Patients with Advanced Solid Tumors

I-Mab Biopharma and TRACON Pharmaceuticals jointly announced that TRACON has dosed the first patient in a US Phase I first-in-human clinical trial of I-Mab’s proprietary CD73 antibody TJD5, also known as TJ004309, in patients with advanced solid tumors. [I-Mab Biopharma] Press Release

‘Tropical Trump’ Sparks Unprecedented Crisis for Brazilian Science

Since Bolsonaro took office in January, Brazil’s researchers have faced funding cuts and repeated attempts by the administration to roll back protections for the environment and Indigenous populations. [Nature News] Editorial

‘No One Is Immune’: Alaska’s Scientists Despair over Plan to Shrink State Universities

The University of Alaska’s governing board plans to consolidate campuses to cope with a 40% cut in state funding. [Nature News] Editorial

NEW 5^th Annual Cell & Gene Therapy Congress
October 24-25, 2019
London, United Kingdom

Visit our events page to see a complete list of events in the community.

NEW Professorship – Innate Immunity and Cardiovascular Repair (Goethe University Frankfurt am Main)

NEW Staff Scientist – Lead Immunotherapy Bioinformatician (Fred Hutchinson Cancer Research Center)

NEW Assistant Professor – Neuro-Immune/Neuro-Pharmacological Interactions (University of Pennsylvania)

NEW Postdoctoral Position – Computational Single-Cell Biology (Max Planck Institute of Immunobiology and Epigenetics)

Scientific Communications Coordinator (STEMCELL Technologies Inc.)

Research Associate – Human Immunology (STEMCELL Technologies Inc.)

Scientist – Human Immunology (STEMCELL Technologies Inc.)

Research Associate – Immune Cell Culture (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Quantitative Microscopy of Immune Cells (National Institute on Aging)

Associate or Full Professor – Neuro-Immune/Neuro-Pharmacological Interactions (University of Pennsylvania)

Postdoctoral Fellow – TCR Immunology/Immune Therapy (The University of Texas MD Anderson Cancer Center)

Senior Scientist – Immuno-Oncology of Hematologic Malignancies (University of Kansas School of Medicine)

Postdoctoral Position – Immunology of Enteric Infections (University of Utah)

Assistant, Associate, or Full Professor – Cancer Immunotherapy/Tumor Immunology (University of California, Irvine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or suggestions? Submit your feedback here.